Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports




Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports



Source link

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *